Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions

Purpose

This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.

Condition

  • Pancreatic Cancer

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of any pancreatic pre-malignant lesion and/or pancreatic malignancy - Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically

Exclusion Criteria

  • Patients with co-existing malignancies of other organs (or a prior history of such) - Patients unable to provide informed consent - Patients unable to complete follow-up

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Case-Only
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Adult patients who undergo EUS-RFA for treatment of pancreatic lesions
  • Device: Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA)
    EUS-guided Radiofrequency Ablation (RFA) consists of the application of alternating current with a frequency of 350-500 kHz (coincidentally the frequency range of radio broadcasts as well) to the target tissue via a special electrode located at the tip of the endoscope.

Recruiting Locations

The University of Texas Health Science Center at Houston
Houston, Texas 77030
Contact:
Amatullah Alibhai, MBA
713-500-6658
Amatullah.Alibhai@uth.tmc.edu

More Details

Status
Recruiting
Sponsor
The University of Texas Health Science Center, Houston

Study Contact

Amatullah Alibhai, MBA
713-500-6658
Amatullah.Alibhai@uth.tmc.edu